Annals of Surgical Oncology

, Volume 8, Issue 1, pp 72–79

Vascular Endothelial Growth Factor Expression in Stage I Non-Small Cell Lung Cancer Correlates With Neoangiogenesis and a Poor Prognosis

  • Helen Han
  • Jan F. Silverman
  • Tibetha S. Santucci
  • Robin S. Macherey
  • Thomas A. dAmato
  • Ming Y. Tung
  • Robert J. Weyant
  • Rodney J. Landreneau
Original Article


Background: Vascular endothelial growth factor (VEGF) plays an important role in tumor growth and metastasis. We investigated the prognostic significance of VEGF overexpression, intratumoral microvessel density (MVD), and angiolymphatic invasion in stage Ia-b non-small cell lung cancer (NSCLC).

Methods: Eighty-five patients undergoing complete surgical resection of pathologic stage Ia-b NSCLC were evaluated. The mean and median clinical follow-up were 37.1 and 39.0 months (range, 30–44 months), respectively. Paraffin-embedded tumor specimens were stained with VEGF and CD31 (a specific endothelial marker) using immunohistochemical methods. VEGF staining was evaluated, by combining both percentage of positive tumor cells and staining intensity, as low (negative and < 20% of tumor cells showing weak positivity), or high (>20% of tumor cells showing strong positivity). CD31 staining was expressed as MVD per high power field at 400× magnification. Angiolymphatic invasion was expressed as either presence or absence.

Results: Low VEGF expression was seen in 25 (29%) patients, and high VEGF expression was seen in 60 (71%) patients. The survival rate in patients with low VEGF expression was significantly higher (80%) than that in those with high VEGF expression (48%, P = .018). The mean MVD in the low VEGF group was 23.7 ± 5.7 vs. 34.4 ± 9.3 in the high VEGF group (P = .001). Patients with high MVD also had a significantly lower survival rate than did those with low MVD count (46% vs. 73%, P = .0053). Age, sex, tumor type, and tumor differentiation were not found to be associated with overall survival. The presence of angiolymphatic invasion and T2 stage (i.e., tumor size > 3 cm) were associated with decreased survival. High VEGF expression, tumor size, and angiolymphatic invasion emerged as three independent factors predicting worsening prognosis using multivariate analysis.

Conclusion: High VEGF expression within stage I NSCLC is closely associated with high intratumoral angiogenesis and poor prognosis. Immunohistochemical evaluation of T stage and VEGF expression along with examination of angiolymphatic invasion perioperatively may aid in predicting prognosis. Adjuvant therapies aimed at retarding tumor angiogenesis may be considered for stage I NSCLC patients with high VEGF levels.

Key Words

Vascular endothelial growth factor (VEGF) Microvessel density CD31 Angiolymphatic invasion Non-small cell lung cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Statistics and Information Department. Vital Statistics 1993, Japan. Vol. 1. Tokyo: Ministry of Health and Welfare, 1995, pp 274–9.Google Scholar
  2. 2.
    Minna JD. Neoplasms of the lung. In Fauci AS et al. (eds). Harrison’s Principles of Internal Medicine. 14th ed. New York: McGraw-Hill, 1998:552–62.Google Scholar
  3. 3.
    Nesbitt JC, Putman JB Jr, Walch GL, Roth JA, Mountain CF. Survival in early stage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466–72.PubMedGoogle Scholar
  4. 4.
    Wada H, Tanaka F, Yanagihara K, et al. Time trends and survival after operations for primary lung cancer from 1976 through 1990. J Thorac Cardiovasc Surg 1996; 112: 349–55.PubMedGoogle Scholar
  5. 5.
    Ginsberg RJ et al. Non-small cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg S et al eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:858–911.Google Scholar
  6. 6.
    Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.PubMedGoogle Scholar
  9. 9.
    Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 1986; 83: 7297–7301.PubMedGoogle Scholar
  10. 10.
    Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9–19.PubMedGoogle Scholar
  11. 11.
    Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–9.PubMedGoogle Scholar
  12. 12.
    Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309–12.PubMedGoogle Scholar
  13. 13.
    Abu JG, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74: 1105–15.Google Scholar
  14. 14.
    Salven P, Heikkla P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997; 76: 930–4.PubMedGoogle Scholar
  15. 15.
    Bayer-Garner IB, Hough AJ, Smoller BR. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness. Mod Pathol 1999; 12: 770–4.PubMedGoogle Scholar
  16. 16.
    Maeda K, Kang S-M, Onoda N, et al. Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 1999; 86: 566–71.PubMedGoogle Scholar
  17. 17.
    Tomoda M, Maehara Y, Kakeji Y, Ohno S, Ichiyoshi Y, Sugimachi K. Intratumoral neovascularization and growth pattern in early gastric carcinoma. Cancer 1999; 85: 2340–6.PubMedGoogle Scholar
  18. 18.
    Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1988; 34: 337–40.Google Scholar
  19. 19.
    Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 85: 1045–9.PubMedGoogle Scholar
  20. 20.
    Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int Oncol 1995; 6: 1059–62.Google Scholar
  21. 21.
    World Health Organization. Histological typing of lung tumors. Tumor 1981; 6: 253–72.Google Scholar
  22. 22.
    Mountain CF. A new international staging system for lung cancer. Chest 1986; 89: 225–32.Google Scholar
  23. 23.
    Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32: 2474–84.CrossRefGoogle Scholar
  24. 24.
    Berse B, Brown LF, van de Water L, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211–20.PubMedGoogle Scholar
  25. 25.
    Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998; 18: 1251–4.PubMedGoogle Scholar
  26. 26.
    Ferrara N. the role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995; 36: 127–37.PubMedGoogle Scholar
  27. 27.
    Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139–47.PubMedGoogle Scholar
  28. 28.
    Ohta Y, Tomita Y, Oda M, Watanabe S, Murakami S, Watanabe Y. Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 1999; 68: 1034–8.PubMedGoogle Scholar
  29. 29.
    Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small cell lung cancer: Prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998; 115: 1007–14.PubMedGoogle Scholar
  30. 30.
    Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 1992; 340: 145–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Yamazaki K, Abe S, Takekawa H, et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer 1974; 74: 2245–50.Google Scholar
  32. 32.
    Ohsawa M, Tomita Y, Kuratsu S, Kanno H, Aozasa K. Angiogenesis in malignant fibrous histiocytoma. Oncology 1999; 52: 51–4.CrossRefGoogle Scholar
  33. 33.
    Goulding H, Rashid NFNA, Robertson JF, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 1995; 26: 1196–1200.PubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2001

Authors and Affiliations

  • Helen Han
    • 1
  • Jan F. Silverman
    • 1
  • Tibetha S. Santucci
    • 2
  • Robin S. Macherey
    • 2
  • Thomas A. dAmato
    • 1
  • Ming Y. Tung
    • 1
  • Robert J. Weyant
    • 3
  • Rodney J. Landreneau
    • 2
    • 4
  1. 1.Department of PathologyAllegheny General Hospital
  2. 2.Department of Cardiothoracic SurgeryAllegheny General Hospital
  3. 3.Department of Cardiothoracic SurgerySchool of Dentistry
  4. 4.Department of Cardiothoracic SurgeryAllegheny General Hospital

Personalised recommendations